Conversations
RSV Vaccination During Pregnancy Cuts Hospitalizations of Infants Under Six Months by 75% in Denmark
Denmark began offering RSV vaccines to pregnant women in October 2025, with 72% uptake among eligible women. The following winter, RSV hospitalizations among infants under six months fell from an average of 1,128 to 296, a 75% decline. High-risk newborns can additionally receive monoclonal antibodies.
A Nature article reports that Denmark introduced a national policy on October 1, 2025, to vaccinate pregnant women against respiratory syncytial virus. Vaccine-induced maternal antibodies can cross the placenta and protect infants for roughly their first six months after birth. High-risk newborns whose mothers were not vaccinated, including premature infants, can receive monoclonal antibody injections.
After analyzing health records, Danish researcher Caroline Klint Johannesen found a significant decline in infant RSV hospitalizations last winter. Vaccination uptake among eligible pregnant women was 72%, and hospitalizations among infants under six months fell from an average of 1,128 to 296, a 75% reduction, equivalent to preventing more than 800 infant hospitalizations in a single epidemic season.
The article also describes the global burden of RSV. The World Health Organization estimates that RSV causes about 3600000 hospitalizations and about 100000 deaths each year among children under five, with 97% of deaths occurring in low- and middle-income countries. The virus also poses risks to older adults; the U.S. CDC estimates that over the past two winters, about 10000 to 25000 people died from it each year, with the elderly population especially prominent.
The report says that since European regulators approved the long-acting monoclonal antibody nirsevimab in 2022, additional antibodies and vaccines for adults have emerged, including one suitable for pregnant women, and dozens of countries in Europe, Asia, and the Americas have introduced different immunization programs.